DSM enters algae alliance
Enlarge image


DSM enters algae alliance

12.10.2012 - Dutch Royal DSM collaborates with a Sanofi subsidiary to stretch ist algal expression system into animal health vaccine production.

This strategic alliance could change the established ways of vaccine production. DSM Nutritional Product, a subsidiary of Dutch Royal DSM N.V., has announced a Development and Option to License Agreement with animal health specialist Merial Limited, part of the US-subsidiary of French Sanofi S.A. The partners want to bring together their expertise to produce animal health vaccines in DSM’s proprietary algal expression system. Compared to existing techniques based on eggs or cell cultures, the new platform could present a faster and more efficient production method. Financial details were not disclosed. It is known, however, that Merial will provide R&D funding to value DSM’s research efforts. DSM would also be eligible to receive milestone payments, license fees and royalties on sales of a successfully launched product.

Almost two years ago Royal DSM acquired Martek Biosciences Corporation from Columbia (Maryland, USA) in a billion dollar deal. This marked DSM’s transformation into a life sciences and materials sciences company. In Columbia omega-3- and omega-6-products are produced by algae. Former Martek CEO Peter Nitze, now President of the Nutritional Lipids division of DSM Nutritional Products, welcomes the expansion of the algae-production portfolio: „We are pleased to join Merial on this important project that we expect will validate the algal expression system as a viable alternative to known vaccine production methods.“ DSM is better known as a global player in biofuel production. The company hit the news earlier this year when it announced the start of a joint venture with US-ethanol producer POET, LLC.



09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015